Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz Phases US Epinephrine Entry

Executive Summary

Sandoz will first focus on the US institutional channel on which it is increasingly concentrating its attention as it rolls out its alternative to Mylan’s EpiPen epinephrine auto-injector.
Advertisement

Related Content

Sandoz Chalks Up A Third US Launch of 2019 With The First Generic Suprane
Sandoz Will Differentiate To Serve A Different World
Sandoz’ Symjepi Set To Undercut Rivals
Teva bags first EpiPen approval
Sandoz bags US epinephrine

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

GB139999

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel